Jobs
-
GlaxoSmithKline and Theravance have announced plans to file a supplemental Japanese New Drug Application for the Relvar/Breo Ellipta fluticasone furoate/vilanterol DPI for the treatment of COPD in the first quarter of 2016. The Japanese MHLW… Read more . . .
-
Nemera has announced that after investing over 10 million euros, it now has the capacity to manufacture up to 45 million units of the Advancia user-independent nasal spray pump per year. The company, which was… Read more . . .
-
RMIT University, located in Melbourn, Australia, has announced that it will display the Respite surface acoustic wave nebulizer at TechInnovation 2015. According to RMIT, the device can deliver drug at rates of 3 ml/min, with… Read more . . .
-
Boehringer Ingelheim’s Spiriva Respimat tiotropium soft mist inhaler has now been approved by the FDA for the treatment of asthma in patients 12 years old and older. Spiriva Respimat was approved for the treatment of… Read more . . .
-
Theravance Biopharma and Mylan announced that they have initiated Phase 3 studies for TD-4208 revefenacin inhalation solution for the treatment of COPD. The Phase 3 program includes 2 12-week efficacy studies plus a 12-month safety… Read more . . .
-
AZTherapies announced that it has initiated a Phase 3 study of its ALZT-OP1 DPI for the treatment of early stage Alzheimer’s disease. ALZT-OP1 is a dry powder formulation of cromolyn and ibuprofen that is delivered… Read more . . .
-
Teva has announced the FDA’s acceptance of a supplemental new drug application (sNDA) for the ProAir RespiClick albuterol DPI for the treatment of asthma in patients aged 4 to 11. The FDA approved ProAir RespiClick… Read more . . .
-
KAER Biotherapeutics has received a $291,000 Phase 1 Small Business Innovation Research (SBIR) grant from the National Heart Lung and Blood Institute of the National Institutes of Health for “Aerosol delivery of Surfactant for ARDS,”… Read more . . .
-
Natesto intranasal testosterone developer Trimel Pharmaceuticals Corporation has announced that it has a new name: Acerus Pharmaceuticals Corporation. Acerus President and CEO Tom Rossi commented, “We are very excited to officially launch our new corporate… Read more . . .
-
GSK and Theravance have announced that a study called SUMMIT (Study to Understand Mortality and MorbidITy in COPD ) showed that COPD patients treated with the Breo/Relvar Ellipta fluticasone furoate/vilanterol DPI had lower risk of… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland